Terumo (OTCMKTS:TRUMY) Upgraded to Hold at Zacks Research

Key Points

• Ratings: Zacks Research upgraded Terumo to a "Hold" and Nomura also raised the stock to "Hold," leaving a consensus rating of "Hold" from two analysts.
• Quarterly results: Terumo reported $0.14 EPS versus $0.15 expected (missed by $0.01) while revenue beat at $1.94 billion versus $1.82 billion expected; net margin was 11.74% and ROE 9.01%.
• Market and valuation: Shares opened at $13.46 and were down about 1.8%, with a market cap of ~$19.85 billion, a P/E of 23.21, and a 52‑week range of $12.15–$20.12.

Terumo (OTCMKTS:TRUMY - Get Free Report) was upgraded by Zacks Research to a "hold" rating in a report released on Thursday,Zacks.com reports.

Separately, Nomura raised shares of Terumo to a "hold" rating in a report on Tuesday, February 24th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Hold".

Terumo Trading Down 1.8%

Shares of Terumo stock opened at $13.46 on Thursday. The company has a market capitalization of $19.85 billion, a P/E ratio of 23.21 and a beta of 0.72. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.89 and a current ratio of 1.51. The company has a fifty day moving average of $13.19 and a 200 day moving average of $14.60. Terumo has a fifty-two week low of $12.15 and a fifty-two week high of $20.12.

Terumo (OTCMKTS:TRUMY - Get Free Report) last issued its earnings results on Friday, February 13th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.82 billion. Terumo had a return on equity of 9.01% and a net margin of 11.74%.

About Terumo

Terumo Corporation OTCMKTS: TRUMY is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.